Background How body size influences risk of molecular subtypes of colorectal cancer (CRC) is unclear. We investigated whether measures of anthropometry differentially influence risk of tumours according to BRAF c.1799T4A p.V600E mutation (BRAF) and microsatellite instability (MSI) status.
Introduction
Although it is well documented that body size influences colorectal cancer (CRC) risk, 1 how this risk differs according to molecular phenotype of tumours is less clear. Elucidating such differences may lead to a better understanding of CRC aetiology and prevention.
One well-defined subgroup of CRC arises through the (sessile) serrated pathway, via serrated epithelium or hyperplastic polyps. 2 A number of genetic and epigenetic abnormalities contribute to the resulting adenoma/carcinoma. The somatic mutation of the BRAF c.1799T4A p.V600E (BRAF) proto-oncogene is thought to occur early in disease progression. 3 Microsatellite instability (MSI), which occurs when short, repetitive DNA sequences undergo an increase or decrease in repeat length, 4 is thought to occur later in the pathway. 2 In sporadic CRC, MSI almost always arises through loss of function in the mismatch repair gene MLH1, resulting from promoter methylation. 2 An underlying abnormality of tumours harbouring a BRAF mutation and/or MSI is the CpG island methylator phenotype (CIMP), 2 which is characterized by numerous promoter CpG island hypermethylated tumour suppressor and DNA repair genes. [5] [6] [7] [8] [9] This in turn is associated with transcriptional silencing of gene expression. 10 Ogino et al. 11, 12 recently described an emerging field of science now referred to as molecular pathological epidemiology. This is the integration of molecular pathology and epidemiology in order to gain insight into potential mechanisms of disease aetiology and to analyse environmental risk factors and disease trends in large numbers of unselected cases. Only a handful studies have investigated the association between body size and characteristics of the (sessile) serrated pathway, and the majority of those was case-control in design and only considered body mass index (BMI) as a risk factor. 4, [13] [14] [15] [16] [17] Central adiposity is thought to be a better predictor of CRC than BMI 18 and height reflects early-life environmental and hormonal exposures, 1 therefore, investigating these risk factors in addition to BMI is warranted.
The Netherlands Cohort Study (NLCS) and the Melbourne Collaborative Cohort Study (MCCS) are prospective cohorts in which colorectal tumour tissue samples have been collected and subsequently analysed for molecular characteristics. We pooled data from individual participants from the two studies to produce a more accurate estimate of relative risk. 19, 20 The purpose of the present study was to investigate if body size (BMI, indicators of central adiposity and height) differentially influence risk of tumours according to BRAF mutation and MSI status.
Materials and Methods
Study populations and design NLCS The NLCS was initiated in 1986 to investigate the association between diet and the development of cancer. It includes 58 279 men and 62 573 women aged 55-69 years at baseline who completed a selfadministered food frequency questionnaire involving 150 food items as well as questions on dietary habits, lifestyle, health and demographics. 21, 22 Municipal registries from throughout The Netherlands were used to constitute an efficient sampling frame. [21] [22] [23] The NLCS uses a case-cohort approach for data processing and analysis; case subjects were derived from the entire cohort and the number of person-years at risk for the entire cohort was estimated from a subcohort of 5000 men and women who were randomly sampled from the full cohort at baseline. All subcohort members who reported prevalent cancer (excluding skin cancer) at baseline were excluded from analyses, leaving 4654. Further details of the NLCS design have been described. [21] [22] [23] Incident CRC cases were identified by annual record linkage to nine regional cancer registries and a national pathology database (PALGA). 24 The completeness of cancer follow-up is almost 100%. 25 Paraffin-embedded tumour material from CRC patients was retrieved, as described previously. 26 In total, 734 incident CRC patients were identified from a follow-up period of 7.3 years after baseline (until December 31, 1993) , excluding the first 2 years of follow-up, of whom a PALGA report of the lesion as well as sufficient DNA were available. 26 The study protocol was approved by the Medical Ethics Committees of the University Hospital Maastricht and TNO Nutrition. Tumour material was collected after approval by the ethical review boards of Maastricht University, the National Cancer Registry and PALGA.
MCCS
The MCCS is a prospective cohort study of 17 045 men and 24 469 women, who were between the age of 27 and 75 years at recruitment from 1990 to 1994 (almost all were aged 40-69 years), and includes 5425 migrants from Italy and 4535 from Greece. For this analysis, 202 participants who had a CRC diagnosed before baseline were excluded, leaving a total of 41 312 individuals. Subjects were recruited via the electoral rolls (registration to vote is compulsory for adults in Australia), advertisements and community announcements in local media (e.g. television, radio and newspapers). Comprehensive lists of Italian and Greek surnames were also used to target Southern European migrants listed in the phone books and on electoral rolls. A structured interview schedule was used to obtain information on potential risk factors. Information on current diet was obtained from a dietary questionnaire that contained a 121-item food frequency questionnaire that was developed for the MCCS. 27 Cases were participants who had a first diagnosis of invasive cancer of the colon or rectum during follow-up to December 31, 2004 , identified by linkage to population-based cancer registries in all Australian states. Addresses and vital status of the subjects were determined by record linkage to electoral rolls, the National Death Index, Victorian death records, from electronic phone books and from responses to mailed questionnaires and newsletters. Archival tumour tissue was sought for all primary, histopathologically confirmed adenocarcinomas diagnosed in Victoria. In the MCCS, 717 tumours were available for analysis.
The study protocol was approved by the Cancer Council Victoria's Human Research Ethics Committee. Participants gave written consent for participation and for the investigators to obtain their medical records.
Anthropometry NLCS Height (cm) and body weight (kg) were self-reported on the baseline questionnaire. BMI was subsequently calculated. At baseline, individuals were also asked to report their lower body (trouser or skirt) clothing size from their clothing label (Dutch sizes). Clothing size appears to predict cancer risk independently of BMI and corresponds to waist measurements. 28 
Height (cm), weight (kg) and waist circumference (cm) were measured at baseline attendance for each participant according to written protocols that were based on standard procedures. 29 Weight was measured to 100 g using digital electronic scales, height to 1 mm using a stadiometer and waist circumference was measured to 1 mm using a 2 -m metal anthropometric tape. BMI was calculated from weight and height.
Molecular pathology
Although CIMP has been measured in both studies, it was not considered here because different methods of measurement were used, leading to different proportions of CRC s showing the phenotype. NLCS BRAF mutation analysis was done by a semi-nested PCR and subsequent restriction fragment length polymorphism (RFLP) analyses as previously described. 30 MSI was determined by a pentaplex PCR using the MSI markers BAT-26, BAT-25, NR-21, NR-22 and NR-24, as described in detail by Suraweera et al.
31
Tumours were classified as MSI-high if two or more markers showed instability and as MSI-low/MS-stable (MSS) if one or none of the markers examined showed instability.
MCCS
BRAF mutation analysis was done by a real-time PCR-based allelic discrimination method. 32 MSI was examined using 10 microsatellite markers. 33 Highfrequency MSI (MSI-H) was defined as 430% instability of at least five markers; low-level MSI (MSI-L) was defined as 1-29% of loci unstable. Tumours were classified as MSI-high, MSI-intermediate, MSI-low and MS-stable, but for comparability with the NLCS, MSI-low and MS-stable were combined into one category.
In both NLCS and MCCS, cases with and without tumour tissue retrieved were similar with respect to established risk factors for CRC, indicating that no selection bias was introduced as a result of inability to retrieval tissue for all cases.
Statistical analyses
Data were analysed with Stata (version 10, Statacorp, College Station, TX, USA). Hazard ratios (HRs), 95% confidence intervals (95% CIs) and P-values were calculated using Cox regression with age as the timescale. 34 To account for its case-cohort design, survival times in the NLCS were adapted using Prentice weights. 35 To estimate HRs separately for different molecular subtypes and to test their difference (i.e. BRAF mutation vs BRAF wild-type), Cox models based on competing risks were fitted using a data duplication method. 36 Person-years of follow-up were calculated from baseline until the date of CRC diagnosis, death or end of follow-up.
Study-specific analyses BMI (per 5 kg/m 2 ) and height (per 5 cm) were fitted as continuous covariates to estimate linear trends on the log hazard scale and as categorical variables. These variables were additionally considered as sexand study-specific quartiles. With respect to waist measurements, trouser/skirt size and waist circumference were fitted categorically for NLCS and MCCS data, respectively, according to approximate sex-specific quartiles. All models were stratified by sex and the MCCS was additionally stratified by ethnicity (based on country of birth and classified into two groups: Southern European (born in Italy or Greece) and Anglo-Celtic (born in Australia, New Zealand, UK or Ireland). 37 Several potential confounding variables were considered for multivariate analysis. For the NLCS, these included family history of CRC (yes/no), smoking status (never smoker, ex-smoker and current smoker), education (primary school, junior high school, senior high school, higher vocational school or university), total energy intake (kcal/day), alcohol intake (0, 0.1-4, 5-14, 15-29 and 530 g/day), recreational physical activity (<30, 30-60, 61-90 and 490 min/day) and consumption of red meat, fruit, vegetables, fibre and grains (g/day). For women, hormonal factors such as contraceptive use (yes/no), HRT use, age at menarche, age at menopause and number of children were also tested. For the MCCS, the variables considered were smoking status (current smoker, former smoker and never smoker), education (primary school, some high/technical school, completed high school and completed tertiary degree/ diploma), total dietary energy intake (kcal/day), current alcohol consumption (males 0, 1-39 and 540 g/day; females 0, 1-19 and 520 g/day), current level of physical activity (none, low, moderate and high), meat, fruit and vegetable (servings/day) intake, fibre from cereal products, multivitamin and fibre supplements (yes/no). For women, parity, total months of lactation for all live births, age at first live birth, age at menarche, HRT use (never, former and current), oral contraceptive pill usage (never and ever), menopausal status and age at menopause were also considered. In the respective studies, no variables changed the estimated HRs by 410% and therefore none was included in the final models.
Pooled analyses
Models were stratified by study, ethnicity and sex. HRs, 95% CIs and P-values were estimated for a 5-kg/m 2 increase in BMI and a 5-cm increase in height. Waist measurement was not considered continuously for the pooled data, because of differences in measurement. BMI, waist measurement and height were additionally considered according to sex and study-specific quartiles. The NLCS was coded to reflect a non-Southern European ethnicity. Due to the increase in sample size, sex-specific analyses were also conducted.
Tests based on Schoenfeld residuals and graphical methods using Kaplan-Meier curves showed no evidence that proportional hazard assumptions were violated for any analyses.
Results
Generally, men and women in the NLCS were older, taller and had a lower BMI than those in the MCCS. There was a higher proportion of current and ex-smokers in the NLCS than in the MCCS (Tables 1 and 2) .
Of the 734 incident tumours in the NLCS, 697 were successfully analysed for BRAF p.V600E c.1799T4A mutation status and 658 for MSI (Table 3) . Of the 717 tumours identified in the MCCS, BRAF mutation status was determined for 582 and MSI status for 585. Further details of the cancers in each cohort are in previous publications. [37] [38] [39] [40] For both studies, 16% of the cancers evaluated had BRAF mutations. In the NLCS, 14% of tumours from males and 19% from females had BRAF mutations, whereas in the MCCS, the proportions were 11 and 19%, respectively. Cases with BRAF mutation tended to be older and taller than non-BRAF cases. With respect to MSI status, 13% of the cancers evaluated in the NLCS and 15% in the MCCS were MSI high. In the NLCS, 12% of the tumours from males and 14% from females were MSI, whereas in the MCCS, the proportions were 12 and 18%, respectively. MSI-high cases tended to be taller than MSS cases Associations between body size and CRC risk according to BRAF status are shown in Table 4 After pooling and considering BMI in sex and studyspecific quartiles, there was a positive dose-response association only for BRAF wild-type tumours and no association with respect to tumours with a BRAF mutation. Tests for heterogeneity between BRAF subtypes were not statistically significant.
With respect to waist measurements in the MCCS, there were similar dose-response associations for both BRAF-mutated and BRAF wild-type tumours when considering quartiles of waist circumference; however, these only reached statistical significance for the BRAF wild-type group. This was also observed in the NLCS for clothing size, although there was less evidence of a dose-response. When the data were pooled, there was a statistically significant positive dose-response association for BRAF wild-type tumours (highest vs lowest quartile HR: 1.59, 95% CI: 1.33-1.90 and P trend < 0.001). A statistically significant trend was also observed for BRAF-mutated tumours (P ¼ 0.03).
When height was modelled per 5-cm increment, there was an increased risk for both tumours with and without BRAF mutations, although the HR was greater for BRAF-mutated tumours. For the pooled data, the HR for tumours with BRAF mutations was 1.23/5-cm increment (95% CI: 1.11-1.37) compared with 1.08 (95% CI: 1.03-1.13) for tumours without The NLCS uses a case-cohort approach for data processing and estimating person-time at risk for the entire cohort. This subcohort consists of 5000 individuals, of whom 4631 were available for the present analysis. b Mean (SD) or percentages where indicated. Ex-drinker 5 3
Low intake 27 19 Medium intake 29 21 High intake 25 17
Education (%)
Primary school 19 20 Some high school 31 43 Completed high school 25 18 Completed tertiary school 25 19 Recreational physical activity (%) Sex-specific categorization. 
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BRAF mutations (P heterogeneity ¼ 0.03). Height was also associated with both tumour subtypes when modelled according to sex-and study-specific quartiles, showing a positive dose-response association that was stronger for mutated than wild-type tumours. Table 5 shows associations according to MSI status. HRs for pooled BMI and waist measurements were similar to those observed for BRAF; a statistically significant association was observed only for MSS tumours. Height was also associated with both tumour subtypes. For the pooled data, the HR for MSI-high tumours was 1.26/5 cm increase (95% CI: 1.13-1.40) compared with 1.08 (95% CI: 1.03-1.14) for MSS tumours (P heterogeneity ¼ 0.02).
Stratifying the analyses according to sex showed no differences between men and women.
Discussion
We present prospective cohort data on associations between body size and molecular subsets of CRC, specifically BRAF mutation and MSI status. We pooled data from the NLCS and MCCS and observed that there was little heterogeneity between tumour subtypes when considering associations according to BMI and waist measurement; however, BMI and waist measurements were strong risk factors for tumours without BRAF mutations or MSI. Interestingly, associations with height showed more heterogeneity; our findings suggest that height is a stronger risk factor for tumours with BRAF mutations or MSI. This is the first molecular pathological epidemiology study to use pooled data from demographically and operationally diverse cohorts. Both the NLCS and MCCS have almost complete ascertainment of CRC and little loss to follow-up. In the MCCS, body size at baseline was measured according to standard protocols. Measures of body size in the NLCS were obtained by self-report; however, there are many examples in the literature showing that this method is a valid and reliable tool for assessing body weight and height in cohort studies. [41] [42] [43] [44] As BRAF-mutated tumours and MSI are uncommon, pooling the NLCS and MCCS allows for greater precision than in the individual studies. Meta-analysis is also a strategy that may be considered when combining the data of studies. With a meta-analysis, analysis can be performed independently at two sites and is therefore more economical and easier to perform than pooling of data. However, an important additional feature of a pooled analysis is that it is carried out on individual data. This means that comparability between two studies can be increased, as study subjects can be reclassified with respect to exposure, outcome and confounders. 45 A case study comparing the outcome of the two approaches suggests that although the approaches differ in the statistical analysis, conclusions reached from meta-analysis and pooled analysis are broadly consistent. 45 To our knowledge, only one study has investigated the association between BMI and BRAF status in CRC tumours. In a case-control study, Slattery et al.
14 reported that obesity (BMI 530 kg/m 2 ) was not associated with BRAF-mutated tumours (associations with BRAF wild-type tumours were not reported). Central adiposity has been identified as a stronger predictor of CRC than BMI 1, 18 and based on our observations, we propose that waist measurements may be a better predictor of CRC than BMI when analysing data according to molecular subtype, especially when there is limited power to detect associations. Furthermore, it may reduce heterogeneity between studies. When HRs were estimated according to waist measurements, the associations observed in the study-specific analyses were more comparable with each other than those observed for BMI and the pooled analysis suggested a dose-response association with respect to both BRAF wild-type and MSS tumours. Future studies should consider this variable in addition to BMI.
Two case-control studies have previously considered the association between BMI and MSI. 4, 46 Whereas the study by Campbell et al. 4 distinguished between MSS and MSI-low tumours, we combined these two groups because our MSI-low group was very small. The presence and role of MSI-low remains controversial. 47 Mutations often observed in MSI-high tumours appear to be absent in MSI-low tumours and no large differences in clinical or molecular characteristics have been observed between MSS and MSI-low patients. 48 Campbell et al. reported that BMI was associated only with MSS and MSI-low tumours, but not MSI-high tumours. We also observed a positive association between BMI and MSS tumours; however, tests for heterogeneity between tumour subtypes did not reach statistical significance in our study. Slattery et al. 46 reported associations according to MSI-positive (equivalent to MSI high) or MSI-negative (equivalent to MSS/MSI-low) status, with findings similar to that of Campbell et al. and additionally reported a positive association between BMI and MSI-positive tumours in women. When we performed sex-specific analyses on the pooled data, we observed no differences between men and women and no associations with MSI tumours. Neither case-control study reported associations according to waist circumference.
A common feature of tumours characterized by BRAF mutations and MSI is CIMP. Although CIMP was measured in both studies, it was not considered here because different methods of measurement were used, leading to different proportions of CRCs showing the phenotype. This highlights a unique challenge of pooling molecular data, as well as the fact that the use of CIMP as an indicator of epigenetic instability has not been without controversy. 49 The association between body size and CIMP has been examined in the NLCS cohort. 16 Although evidence [50] [51] [52] in the NLCS, associations were considered according to CIMP-high and CIMPnegative tumours and those data suggested that a large body size increases the risk of both subtypes. This supports the observations reported in the present article.
Our observations from the pooled data are intriguing. For all molecular subtypes considered, we observed positive associations, which is consistent with substantial evidence that adult attained height is a strong risk factor for CRC in general. 1 However, HRs were significantly higher for tumours with BRAF mutations and MSI than for BRAF wild-type or MSS tumours, respectively. Height is a marker of an aggregated fetal and childhood experience and can be considered a proxy measure for important nutritional exposures, which affect several hormonal and metabolic axes. 1 Several studies show that childhood energy restriction is associated with a decreased risk of CRC later in life. [53] [54] [55] [56] [57] Furthermore, we recently reported from the NLCS that exposure to severe energy restriction during childhood and adolescence was associated with a low risk of developing a CIMP-positive tumour. 58 Although little research has been done in this area, our current findings contribute to the hypothesis that genetic and epigenetic events in CRC development may be influenced by early-life environmental exposures. This hypothesis may explain why there was little heterogeneity between tumour subtypes when considering associations according to BMI and waist circumferences; these were measured at baseline in adulthood. Analysing additional cohorts to draw firmer conclusions is necessary.
Conclusion
In conclusion, our findings reiterate the importance of a healthy body weight in CRC prevention. Furthermore, positive associations between height, BRAF mutation and MSI provide more evidence for the hypothesis that early life events may influence genetic and epigenetic mechanisms. 
